Inherent Biosciences, Inc. Awarded NIH SBIR Phase I Grant to Commercialize Innovative Diagnosis of Non-Obstructive Azoospermia (The Most Severe Form of Sperm Dysfunction)
April 13, 2022 09:11 ET | Inherent Biosciences Inc
SALT LAKE CITY, April 13, 2022 (GLOBE NEWSWIRE) -- Inherent Biosciences, a biotechnology company pioneering epigenetic medicine, today announced an award from the National Institute of Child Health...
Epigenetics Global and Regional Market Analysis: A $14,311.1 Million Market by 2031, Growing at a CAGR of 17% During 2021-2031
February 21, 2022 04:08 ET | Research and Markets
Dublin, Feb. 21, 2022 (GLOBE NEWSWIRE) -- The "Epigenetics Market - A Global and Regional Analysis: Focus on Product, Mechanism, Technology, Application, End User, and Region - Analysis and...
SalariusLogo2ColorNoTag.jpg
Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational 2022 Virtual Conference
February 17, 2022 08:01 ET | Salarius Pharmaceuticals, Inc.
HOUSTON, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
SalariusLogo2ColorNoTag.jpg
Salarius Pharmaceuticals to Participate in the 2022 BIO CEO & Investor Conference
February 08, 2022 08:00 ET | Salarius Pharmaceuticals, Inc.
HOUSTON, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
salarius-logo-rgb-72dpi.jpg
Salarius Pharmaceuticals to Present at the Virtual Life Science Investor Forum
December 15, 2021 08:31 ET | Salarius Pharmaceuticals, Inc.
HOUSTON, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
salarius-logo-rgb-72dpi.jpg
Salarius Pharmaceuticals to Participate in Annual Benchmark Company Discovery One-on-One Conference
November 29, 2021 08:01 ET | Salarius Pharmaceuticals, Inc.
HOUSTON, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
Inherent Biosciences Launches Path Fertility - Epigenetic Sperm Quality Test (SpermQT)
October 18, 2021 09:12 ET | Inherent Biosciences Inc
SALT LAKE CITY, Oct. 18, 2021 (GLOBE NEWSWIRE) --  Inherent Biosciences, a molecular diagnostics company at the intersection of epigenetics and artificial intelligence (AI), today announced the...
Proteintech Expands Collaboration With Epigenetics Company Active Motif
September 08, 2021 16:55 ET | Proteintech Group Inc.
ROSEMONT, Ill., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Proteintech Group, an original manufacturer of antibodies, nanobodies and recombinant proteins, today announced that it has made a strategic...
22157.jpg
CRISPR and Cas Genes Markets, 2028 by Product & Service (Vector-based Cas, DNA-free Cas), Application (Biomedical, Agriculture)
June 16, 2021 06:08 ET | Research and Markets
Dublin, June 16, 2021 (GLOBE NEWSWIRE) -- The "CRISPR and Cas Genes Market Size, Share & Trends Analysis Report by Product & Service (Vector-based Cas, DNA-free Cas), by Application...
CPI Logo-Color.png
Constellation Pharmaceuticals Provides an Update from the Ongoing MANIFEST Study of Pelabresib
June 11, 2021 09:00 ET | Constellation Pharmaceuticals , Inc.
Translational data support the disease-modifying potential of pelabresibCentral pathology review confirmed bone marrow fibrosis improvements observed with pelabresib treatment Impact of pelabresib...